Date:5/25/2011

lly from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q.  Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov
'/>"/>

SOURCE Vermillion, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
2. Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011
3. Stephens Initiates Coverage on Vermillion
4. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
5. Vermillion Announces Issuance of European Patent
6. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
7. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
8. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
9. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
10. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
11. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer